



**Living Cell Technologies Limited**

**COMPANY ANNOUNCEMENT:**

**Living Cell Technologies Raises A\$4.2m From A Placement Of Shares To Fund Clinical Trials Of DIABECCELL®**

**30 July 2009: Sydney, Australia, Auckland, New Zealand – Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY)** announced that it has closed a private placement of share capital raising A\$4.2m. The placement provides for the issue of up to 25.5m ordinary shares at A\$0.165 with a 2 for 5 option attached (10.2m options), exercisable at any time until 31 December 2010 at A\$0.24 per share. The \$0.165 issue price is a 14.37% discount for the 5 day volume weighted average price to 27 July 2009.

The above securities will be issued within the 15% limit provided in ASX Listing Rule 7.1 and as such do not require shareholder approval.

The funds will be used as working capital for the New Zealand clinical trial of DIABECCELL® and to complete the dose finding trial in Russia and for operations supporting these trials.

CEO Dr Paul Tan said "It is pleasing to receive investor support for the company to fund the trial in New Zealand, following the promising results from the trial in Russia".

DIABECCELL® is LCT's lead product designed to normalize blood glucose levels in type 1 diabetes sufferers. DIABECCELL® comprises encapsulated porcine insulin-producing cells which can be administered without the need to use immunosuppressive drugs.

-Ends-

**For further information: [www.lctglobal.com](http://www.lctglobal.com)**

Dr. Paul Tan  
Chief Executive Officer  
Mob: 021 608 784 (NZ)  
Tel: +64 9 276 2690  
[ptan@lctglobal.com](mailto:ptan@lctglobal.com)

Prof. Bob Elliott  
Medical Director  
Mob: +64 27 292 4177  
Tel: +64 9 276 2690  
[belliott@lctglobal.com](mailto:belliott@lctglobal.com)

Mr John Cowan  
Finance & Administration Manager  
Tel: +64 9 276 2690  
[jcowan@lctglobal.com](mailto:jcowan@lctglobal.com)

Paul Dekkers  
Investor and Media Relations  
Tel: +612 9237 2800  
[pdekkers@bcg.com.au](mailto:pdekkers@bcg.com.au)

**About Living Cell Technologies: [www.lctglobal.com](http://www.lctglobal.com)**

*Living Cell Technologies (LCT) is developing cell-based products to treat life threatening human diseases. The Company owns a biocertified pig herd that it uses as a source of cells for treating diabetes and neurological disorders. For patients with Type 1 diabetes, the Company transplants microencapsulated islet cells so that near-normal blood glucose levels may be achieved without the need for administration of insulin or at significantly reduced levels. The Company entered*



*clinical trials for its diabetes product in 2007. For the treatment of Parkinson's disease and other neurological disorders, the company transplants microencapsulated choroid plexus cells that deliver beneficial proteins and neurotrophic factors to the brain. LCT's technology enables healthy living cells to be injected into patients to replace or repair damaged tissue without requiring the use of immunosuppressive drugs to prevent rejection. LCT also offers medical-grade porcine-derived products for the repair and replacement of damaged tissues, as well as for research and other purposes.*

#### **LCT Disclaimer**

This document contains certain forward-looking statements, relating to LCT's business, which can be identified by the use of forward-looking terminology such as "promising," "plans," "anticipated," "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to," "potential," "seeking to," "goal," "could provide," "intends," "is being developed," "could be," "on track," or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. LCT is providing this information and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.